A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 264-270

  García Lerma, J Gerardo ^a   Schinazi, Raymond F ^b   Juodawlkis, Amy S ^b   Soriano, Vincent ^c   Lin, Yulin ^b   Tatti, Kathleen ^b   Rimland, David ^b   Folks, Thomas M ^a   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS TRANSMISSION;

EID: 0033039932     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.264     Document Type: Article

References (43)

1. Arts, E. J., and M. A. Wainberg. 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:527-540.
2. Arts, E. J., J. Marois, Z. Gu, S. F. J. Le Grice, and M. A. Wainberg. 1996. Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70:712-720.
3. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Caroline, M. P., and D. Faulds. 1997. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53:657-680.
5. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA panel. JAMA 277:1962-1969.
6. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
7. Conlon, C. P., P. Klenerman, A. Edwards, B. A. Larder, and R. E. Phillips. 1994. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J. Infect. Dis. 169:411-415.
8. D'Aquila, R. T. 1996. Nucleosides and foscarnet: clinical aspects, p. 191-224. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons, Inc., New York, N.Y.
9. Erice, A., D. L. Mayers, D. G. Strike, K. J. Sannerud, F. E. McCutchan, K. Henry, and H. H. Balfour. 1993. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328: 1163-1165.
10. Eriksson, B. F. H., C. K. Chu, and R. F. Schinazi. 1989. Phosphorylation of 3′-azido-2′,3′-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5′-triphosphate. Antimicrob. Agents Chemother. 33:1729-1734.
11. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gockle, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
12. Garcia Lerma, J. G., S. Yamamoto, M. Gomez-Cano, V. Soriano, T. A. Green, M. P. Busch, T. M. Folks, and W. Heneine. 1998. Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT. J. Infect. Dis. 177:1221-1229.
13. Gulick, R. M., J. W. Mellors, D. Havlir, J. E. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
14. Heneine, W., S. Yamamoto, W. M. Switzer, T. J. Spira, and T. M. Folks. 1995. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 171:1210-1216.
15. Heneine, W., J. G. Garcia Lerma, J. G. Vazquez-Rosales, S. Qari, A. Juodawlkis, D. Havlir, R. F. Schinazi, D. D. Richman, and T. M. Folks. 1998. A novel non culture-based approach for the rapid analysis of phenotypic resistance to reverse transcriptase inhibitors of HIV-1 from plasma, abstr. 63, p. 42. In Program and abstracts of the 2nd International Workshop on Drug Resistance and Treatment Strategies.
16. Hertogs, K., M. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
17. Imrie, A., A. Beveridge, W. Genn, J. Vizzard, D. A. Cooper, and the Sydney Primary HIV Infection Study Group. 1997. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J. Infect. Dis. 175:1502-1506.
18. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
19. Jellinger, R. M., R. W. Shafer, and T. C. Merigan. 1997. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. J. Infect. Dis. 175:561-566.
20. Kavlik, M. F., K. Wyvill, R. Yarchoan, and H. Mitsuya. 1998. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis. 177:1506-1513.
21. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir. Res. 28:133-146.
22. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
23. Kusumi, K., B. Conway, S. Cunningham, A. Berson, C. Evans, A. K. Iversen, D. Colvin, M. V. Gallo, S. Coutre, and E. G. Shpaer. 1992. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J. Virol. 66:875-885.
24. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 246: 1155-1158.
25. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
26. Larder, B. A., A. P. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT+3TC combination therapy. Science 269:696-699.
27. Li, Y., J. C. Kappes, J. A. Conway, R. W. Price, G. M. Shaw, and B. H. Hahn. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65:3973-3985.
28. Ludwig, J., and F. Eckstein. 1989. Rapid and efficient synthesis of nucleoside 5′-O-(1-thiotriphosphates), 5′-triphosphates and 2′3′-cyclophosphorothioates using 2-chlore-4H-1,2,3-benzodioxaphosphorin-4-one. J. Org. Chem. 54: 631-635.
29. Sarafinos, S. G., V. N. Pandey, N. Kaushik, and M. J. Modak. 1995. Glutamine 151 participates in the substrate dNTP binding function of HIV-1 reverse transcriptase. Biochemistry 34:7207-7216.
30. Schinazi, R. F., A. McMillan, D. Cannon, R. Mathis, R. M. Lloyd, A. Peck, J Sommadossi, M. St. Clair, J. Wilson, P. A. Furman, G. Painter, W. Choi, and D. C. Liotta. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431.
31. Schinazi, R. F., R. M. Lloyd, M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
32. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 5:129-142.
33. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. Boucher. 1995. Rapid changes in HIV-1 RNA load and appearance of drug-resistant virus population in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
34. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and the AIDS Clinical Trials Group 143 Virology Team. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172:70-78.
35. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
36. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
37. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. F. Schinazi, and R. Rossau. 1997. Line probe assay for the rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41: 284-291.
38. Tisdale, N., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
39. Veenstra, J., R. Schuurman, M. Cornelissen, A. B. van't Wout, C. A. B. Boucher, H. Schuitemaker, J. Goudsmit, and R. A. Coutinho. 1995. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. J. Infect. Dis. 21:556-560.
40. Wainberg, M. A., H. Salomon, Z. Gu, J. S. G. Montaner, T. P. Cooley, R. MaCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9: 351-357.
41. Wainberg, M. A., M. Hsu, Z. Gu, G. Borkow, and M. A. Parniak. 1996. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10:S3-S10.
42. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, and J. Cherrington. 1998. The M184V substitution in reverse transcriptase moderately increases sensitivity of HIV-1 to PMPA, abstr. 680, p. 207. In Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
43. Yamamoto, S., T. M. Folks, and W. Heneine. 1996. Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems. J. Virol. Methods 61:135-143.